IGFN1 (EEF1A2BP1): A Potential Drug Target and Biomarker for Inflammatory Neoplasia

Target Name: IGFN1

NCBI ID: G91156

IGFN1

IGFN1 (EEF1A2BP1): A Potential Drug Target and Biomarker for Inflammatory Neoplasia

Introduction

Inflammatory neoplasia (IN) refers to the formation of new tissues or organs in the body due to an inflammatory response. This process can lead to various diseases, including cancer, autoimmune diseases, and chronic inflammatory disorders. Although there are several established treatments for IN , the lack of effective therapies for certain individuals and the high recurrence rates of some diseases remain significant challenges. Therefore, identifying potential drug targets and biomarkers for IN is crucial for improving treatment outcomes.

IGFN1 (EEF1A2BP1), a gene encoding a protein known as insulin-like growth factor (IGF), is a potential drug target and biomarker for IN. IGF plays a crucial role in cell growth, differentiation and metabolism, and has been implicated in various INs. IGF-1 has been shown to promote the growth and survival of cancer cells and has been identified as a potential therapeutic target in INs.

IGFN1 function and role in INs

IGF-1 is a transmembrane protein that belongs to the insulin-like growth factor (IGF) family. It consists of four distinct isoforms: IGF-1, IGF-2, IGF-3, and IGF-4. IGF-1 is the most abundant isoform and is responsible for most of the physiological functions of IGFs. IGF-1 functions by promoting cell growth, differentiation, and metabolism through a variety of signaling pathways, including TGF-β, FGF, and Wnt.

In addition to its role in cell growth and differentiation, IGF-1 has also been implicated in the regulation of cell survival and stress responses. IGF-1 has been shown to promote the survival of cancer cells by inhibiting cell apoptosis and activating cell stress- induced signaling pathways. IGF-1 has also been shown to play a role in the regulation of inflammation and immune cell function.

IGFN1 as a drug target

The potential of IGF-1 as a drug target for IN is based on its role in promoting the growth and survival of cancer cells. Several studies have shown that IGF-1 can promote the growth of various IN cell types, including neural cells, endothelial cells, and cancer cells. IGF-1 has also been shown to enhance the sensitivity of cancer cells to chemotherapy and radiation therapy.

One of the main advantages of IGF-1 as a drug target is its potential to target a wide range of cancer types, including malignant and benign neoplasms. This is because IGF-1 signaling pathways are highly conserved across different cancer types, which means that targeting IGF-1 may be an effective way to develop new treatments for a broad range of INs.

IGFN1 as a biomarker

IGF-1 has also been identified as a potential biomarker for IN. Several studies have shown that IGF-1 levels are elevated in various IN tissues and that they can be used as a diagnostic or predictive marker for IN. For example, IGF-1 has been shown to be increased in the primary and metastatic tissues of various INs, including breast, ovarian, and colorectal cancers.

In addition to its potential as a diagnostic or predictive marker, IGF-1 has also been shown to be a potential therapeutic target in IN. By inhibiting IGF-1 signaling pathways, researchers have shown that they can reduce the growth and survival of IN cells . This suggests that targeting IGF-1 may be an effective way to develop new treatments for IN.

Conclusion

IGFN1 is a potential drug target and biomarker for IN. Its functions in cell growth, differentiation, and metabolism, as well as its role in the regulation of cell survival and stress responses, make IGF-1 an attractive target for the development of new treatments for IN. Furthermore, IGF-1 has also been shown

Protein Name: Immunoglobulin Like And Fibronectin Type III Domain Containing 1

The "IGFN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets